1
|
Charles J, Mouret S, Challende I, Leccia MT, De Fraipont F, Perez S, Plantier N, Plumas J, Manuel M, Chaperot L, Aspord C. T-cell receptor diversity as a prognostic biomarker in melanoma patients. Pigment Cell Melanoma Res 2020; 33:612-624. [PMID: 31971658 DOI: 10.1111/pcmr.12866] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Revised: 01/06/2020] [Accepted: 01/14/2020] [Indexed: 11/30/2022]
Abstract
There is increasing evidence that T-cell receptor (TCR) repertoire diversity can be a predictive biomarker of immune responses in cancer patients. However, the characteristics of the T-cell repertoire together with its prognostic significance in melanoma patients and impact on disease progression remain unknown. We investigated the combinatorial TCR repertoire diversity by semi-quantitative multi-N-plex PCR in peripheral blood samples from 44 melanoma patients together with seven matched metastatic lymph nodes and explored its potential predictive value on clinical prognosis. The diversity was quantified by calculating both richness (number of different specificities) and evenness (relative abundance of the different specificities). Our results revealed that a higher TCR repertoire diversity in blood of patients was associated with a longer PFS, while divpenia (low repertoire diversity) was linked with poor prognosis. The diversity was significantly higher in patients undergoing late relapse and long survival compared to patients who progressed rapidly. Interestingly, the TCR repertoire diversity in tumor may have a potential prognostic value. Thus, our study highlights that the TCR repertoire diversity is a prognostic indicator of clinical outcome in patients with melanoma.
Collapse
Affiliation(s)
- Julie Charles
- Immunobiology and Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, Grenoble, France.,Dermatology Clinic, Grenoble University Hospital, Grenoble, France
| | - Stephane Mouret
- Dermatology Clinic, Grenoble University Hospital, Grenoble, France
| | | | - Marie-Therese Leccia
- Immunobiology and Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, Grenoble, France.,Dermatology Clinic, Grenoble University Hospital, Grenoble, France
| | - Florence De Fraipont
- Department of Biochemistry of Cancers and Biotherapies, Grenoble University Hospital, Grenoble, France
| | | | | | - Joel Plumas
- Immunobiology and Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, Grenoble, France.,R&D-Laboratory, Etablissement Français du Sang Auvergne Rhone-Alpes, Grenoble, France
| | | | - Laurence Chaperot
- Immunobiology and Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, Grenoble, France.,R&D-Laboratory, Etablissement Français du Sang Auvergne Rhone-Alpes, Grenoble, France
| | - Caroline Aspord
- Immunobiology and Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, Grenoble, France.,R&D-Laboratory, Etablissement Français du Sang Auvergne Rhone-Alpes, Grenoble, France
| |
Collapse
|
2
|
Bondier L, Tardieu M, Leveque P, Challende I, Pinel N, Leccia MT. Cutaneous Collagenous Vasculopathy: Report of Two Cases Presenting as Disseminated Telangiectasias and Review of the Literature. Am J Dermatopathol 2017; 39:682-688. [DOI: 10.1097/dad.0000000000000613] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Bondier L, Tardieu M, Leveque P, Challende I, Pinel N, Leccia MT. Vasculopathie cutanée collagénique : 2 cas et revue de la littérature. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
4
|
Sabatier-Vincent M, Charles J, Pinel N, Challende I, Claeys A, Leccia MT. [Acantholytic dermatosis in patients treated by vemurafenib: 2 cases]. Ann Dermatol Venereol 2014; 141:689-93. [PMID: 25442474 DOI: 10.1016/j.annder.2014.09.024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2014] [Revised: 07/17/2014] [Accepted: 09/01/2014] [Indexed: 12/15/2022]
Abstract
BACKGROUND Acantholytic dyskeratosis under BRAF inhibitors are dermatological diseases rarely reported to date. PATIENTS AND METHODS We report 2 cases of acantholytic dyskeratosis, reaching the trunk and the seborrheic zones, not itchy, appeared one month after the introduction of vemurafenib. The histological analysis was typical of a "Grover-like rash" for the 2 patients. DISCUSSION The appearance of acantholytic dyskeratosis under vemurafenib, a BRAF inhibitor, seems related with a paradoxical activation of the MAP-kinases pathway and with a growth acceleration of lesions in which RAS mutations of keratinocytes. Theses dermatoses seem also to occur with dabrafenib. CONCLUSION The patients treated by BRAF inhibitors (vemurafenib and dabrafenib) can present acantholytic dyskeratosis. The arisen of this mild dermatosis does not question, of course, the continuation of the treatment. These cutaneous manifestations can be managed with emollients.
Collapse
Affiliation(s)
- M Sabatier-Vincent
- Clinique de dermatologie et photobiologie, hôpital Nord, CHU de Grenoble, Cs 10217, boulevard de la-Chantourne-La-Tronche, 38043 Grenoble cedex 9, France.
| | - J Charles
- Clinique de dermatologie et photobiologie, hôpital Nord, CHU de Grenoble, Cs 10217, boulevard de la-Chantourne-La-Tronche, 38043 Grenoble cedex 9, France
| | - N Pinel
- Département d'anatomie pathologique, CHU de Grenoble, Cs 10217, 38043 Grenoble cedex 9, France
| | - I Challende
- Clinique de dermatologie et photobiologie, hôpital Nord, CHU de Grenoble, Cs 10217, boulevard de la-Chantourne-La-Tronche, 38043 Grenoble cedex 9, France
| | - A Claeys
- Clinique de dermatologie et photobiologie, hôpital Nord, CHU de Grenoble, Cs 10217, boulevard de la-Chantourne-La-Tronche, 38043 Grenoble cedex 9, France
| | - M-T Leccia
- Clinique de dermatologie et photobiologie, hôpital Nord, CHU de Grenoble, Cs 10217, boulevard de la-Chantourne-La-Tronche, 38043 Grenoble cedex 9, France
| |
Collapse
|